← Eichor
Condition: Advanced Esophageal Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Esophageal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinom
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT07188103A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
NA · 1 location(s) · Tanta University · NCT06961526Chemoradiotherapy for Advanced Esophageal Cancer
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT02297217A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05624099Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05392413Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
NA · 1 location(s) · Anhui Provincial Hospital · NCT06602843Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT06753747At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer
NA · 1 location(s) · Fudan University · NCT07272382A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Phase 1/Phase 2 · 22 location(s) · Merck Sharp & Dohme LLC · NCT07405151Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT07070466Folfox+Irinotecan+Chemort In Esophageal Cancer
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04656041A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophag
Phase 3 · 1 location(s) · Renmin Hospital of Wuhan University · NCT05919030A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Phase 1 · 3 location(s) · Fox Chase Cancer Center · NCT05274048A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 14 location(s) · Kyowa Kirin Co., Ltd. · NCT06248411Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.